FOLLOW US

LANGUAGE
繁中 EN
HOME R&D New Drug
Pipeline New Drug
DRUG
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/Market

CBL-514

Injection
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/Market

Non-Surgical Fat Reduction

Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/Market

Dercum’s Disease

Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/Market

Cellulite

Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/Market
DRUG
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/Market

CBA-539

Injection
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/Market

Hyperpigmentation, Skin Aging

Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/Market
DRUG
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/Market

CBO-012

Injection
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/Market

Osteoarthritis

Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/Market
Drugs mentioned on this website are under clinical study and for information only, not intended for the diagnosis, cure, mitigation, treatment, or disease prevention.
NEW DRUG

  • CBL-514

    Injection

    First-in-class new drug that can trigger adipocyte apoptosis at the injection site. It can effectively reduce the subcutaneous fat without causing tissue necrosis or prominent side effects.

    LEARN MORE

    CBL-514

    Injection

  • CBA-539

    Injection

    Long-acting sustained-release injection, which can inhibit the production and transmission of melanin, reduce spots, and promote the proliferation of autologous collagen, to achieve the anti-aging effect with increase of skin elasticity.

    LEARN MORE

    CBA-539

    Injection

  • CBO-012

    Injection

    Long-acting sustained-release injection, which can reduce inflammatory factors, slow down cartilage degradation and wear, and reduce hard bone loss.

    LEARN MORE

    CBO-012

    Injection
WeChat

Search

LANGUAGE
繁中 EN

CONTACT

32F.-9, No.99, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City 221, Taiwan (R.O.C.)

TEL +886-2-2697-1355

FAX +886-2-2697-2508 ; +886-2-2697-1369

info@caliway.com.tw

CALIWAY. All Rights Reserved.
Design By iBest